PUBLIC RELEASE DATE: <\/p>\n
13-Nov-2014 <\/p>\n
Contact: Kathryn Ryan kryan@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News @LiebertOnline<\/p>\n New Rochelle, NY, November 13, 2014--The two U.S. FDA approved oligonucleotide-based drugs on the market both have a modified chemical backbone made of phosphorothioates. The therapeutic advantages of the phosphorothioate group and the new types of gene expression-regulation oligonucleotide drugs that it is enabling are detailed in a Review article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available free on the Nucleic Acid Therapeutics website until December 13, 2014. <\/p>\n In the article \"Phosphorothioates, Essential Components of Therapeutic Oligonucleotides,\" Fritz Eckstein, Max-Planck-Institut fr Experimentelle Medizin, Gttingen, Germany, describes how the chemical and biochemical properties of this significant nucleic acid modification have made DNA suitable for use as therapeutic agents. Initial applications focused on cleaving the mRNA product of genes to block protein production. Dr. Eckstein explores novel applications including microRNA and long non-coding RNA targets and the use of decoy oligonucleotides. <\/p>\n \"We will advance the field of nucleic acid therapeutics by looking to key opinion leaders to educate and initiate the experienced and newcomers alike. In this review, Dr. Eckstein has produced a tour de force concerning the therapeutic application of phosphorothioates,\" says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI. <\/p>\n ### <\/p>\n Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD. <\/p>\n About the Journal <\/p>\n Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics website. <\/p>\n <\/p>\n More: <\/p>\n Modified DNA backbone enables success of existing and novel oligonucleotide therapeutics<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" PUBLIC RELEASE DATE: 13-Nov-2014 Contact: Kathryn Ryan kryan@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News @LiebertOnline New Rochelle, NY, November 13, 2014--The two U.S. Continue reading